Posted by Michael Wonder on 22 Oct 2024
ICER publishes final evidence report on treatments for transthyretin amyloid cardiomyopathy
21 October 2024 - Independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for tafamidis, acoramidis, and vutrisiran when compared to no disease-specific therapy; tafamidis and acoramidis would achieve common thresholds for cos -effectiveness if priced between $13,600 - $39,000/year.
The ICER today released a final evidence report assessing the comparative clinical effectiveness of tafamidis (Vyndamax/Vyndaqel, Pfizer), acoramidis (BridgeBio Pharma) and vutrisiran (Amvuttra, Alnylam Pharmaceuticals) for the treatment of transthyretin amyloid cardiomyopathy.
